@article{TCR29904,
author = {Alfonso Fiorelli and Fabiana Vitiello and Floriana Morgillo and Mario Santagata and Chiara Spuntarelli and Marina Di Domenico and Mario Santini and Andrea Bianco},
title = {Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?},
journal = {Translational Cancer Research},
volume = {8},
number = {Suppl 6},
year = {2019},
keywords = {},
abstract = {In the immunotherapy possibilities, pembrolizumab appeared as a leader, along with nivolumab and atezolizumab, in the second-line setting (1). In the last years, the results of phase III KEYNOTE trials (2-6) confirmed the Pembrolizumab as ahead of other checkpoint inhibitors in the first-line setting. Firstly, KEYNOTE-10 (7) showed that the PD-1 inhibitor represented a standard second-line treatment option in NSCLC as it significantly improved OS in comparison with docetaxel following prior platinum-based chemotherapy.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/29904}
}